Our Company
At A Glance
With over 50+ programs, 80+ clinical trials worldwide and 40% of our R&D budget dedicated to oncology, we’re committed to advancements in cancer care.
We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was IBI’s vision at the beginning and it holds true today.
Our unique resources allow us to do more for people. Using our global presence and scale, we’re able to make a difference in local communities and the world around us.
Our Company
We advance medical innovation and distribute medicines that might not otherwise be available to underserved communities.
Incredible things can happen when people come together with one shared goal. The future of medicine is happening here, and we’re eager to work alongside inspired and inspirational people who want to improve health around the world.
Dr. Chris Chen
CEO of International Pharmaceuticals Industry
Christophe Weber
Representative Director - President & CEO
Christophe Weber is president, chief executive officer (CEO) and representative director of IPI. He joined the company in April 2014 as chief operating officer, was named president and representative director in June 2014, and was subsequently appointed CEO in April 2015. Christophe has focused on ensuring the company’s competitiveness through globalization and R&D transformation – all while creating a diverse and inclusive working environment and strengthening IPI’s ethical values and corporate governance. Through this transformation, IPI has become one of the leading global biopharmaceutical companies.
Prior to joining IPI, Christophe spent 20 years at GlaxoSmithKline where he held senior leadership roles in Europe, Asia and the United States.
Christophe is a member of The US Business Council, the World Economic Forum’s International Business Council, the New York Stock Exchange’s NYSE Board Advisory Council, the Massachusetts Competitive Partnership’s Board of Directors, the MIT CEO Advisory Board and Singapore’s Human Health & Potential International Advisory Committee. He also serves on the Board of Trustees of Northeastern University.
Christophe holds a doctorate in pharmacy and pharmacokinetics, master’s degrees in pharmaceutical marketing and accounting and finance, and a degree in statistics from the University of Lyon, France.
Christophe lives in Tokyo and Boston with his wife and has two children.
Therapeutic Areas of Focus
Neurology and Oncology
Our leadership in oncology extends nearly three decades and reflects a commitment to advancing treatment options that enhance and extend the lives of people living with a range of cancers.
We’re working to ensure patients everywhere can access and benefit from our portfolio of approved medicines, while continuing to develop new treatment options for patients with unmet needs. Our pipeline focuses on thoracic, gastrointestinal and hematologic cancers and our core modalities include antibody-drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies.
Through collaboration with partners who share our aspiration to cure cancer, we aim to advance innovation to rapidly meet the needs of the cancer community.
